MoneyWorks4Me

USFDA concludes PAI at Jubilant Pharmova’s arm's facility at Roorkee

02 Aug 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded pre-approval inspection (PAI) at Jubilant Pharmova’s stepdown subsidiary -- Jubilant Generics' solid dosage formulations facility at Roorkee site, India.  The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.

The site’s revenue from the US market in the trailing twelve-month period (July 2024 to June 2025) is less than one percent of Jubilant Pharmova revenues in the same period.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

931.75 6.75 (0.73%)
07-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1949.00
Dr. Reddys Labs. 1172.00
Cipla 1472.00
Lupin 2360.00
Zydus Lifesciences 1115.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: